Healthcare / Medical DevicesNasdaqGM
$23.98
-0.63 (-2.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $38.1M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$541M
P/E
27.6x
↑EV/EBITDA
12.6x
↑ROE
8.7%
↑Gross Margin
75.9%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
+19.2%
FCF CAGR
—
FCF margin
12.2%
FCF / Net income
2.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $329.5M · net income $19.1M · FCF $40.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $329.5M | $329.5M | $293.0M | $274.4M | $246.8M | $208.1M | $187.1M | $189.5M | $143.8M | $109.3M | $84.5M | $62.9M | $47.7M |
| Net Income | $19.1M | $19.1M | $17.0M | $28.5M | $-17.9M | $-11.8M | $-620000.00 | $11.0M | $6.6M | $5.9M | $2.9M | $1.4M | $2.1M |
| EBITDA | $39.0M | $39.0M | $32.4M | $26.5M | $1.7M | $1.9M | $-834000.00 | $14.0M | $6.7M | $5.7M | $5.1M | $4.3M | $4.5M |
| EPS | 0.82 | 0.82 | 0.70 | 1.23 | -0.89 | -0.60 | -0.03 | 0.56 | 0.34 | 0.31 | 0.15 | -0.15 | 0.02 |
| Gross Margin | 75.9% | 75.9% | 74.0% | 71.1% | 71.3% | 71.2% | 71.0% | 70.8% | 71.1% | 73.4% | 72.9% | 73.1% | 73.4% |
| Operating Margin | 8.9% | 8.9% | 7.6% | 6.6% | -5.2% | -0.8% | -1.9% | 5.5% | 2.1% | 3.6% | 5.1% | 5.5% | 8.0% |
| Net Margin | 5.8% | 5.8% | 5.8% | 10.4% | -7.2% | -5.7% | -0.3% | 5.8% | 4.6% | 5.4% | 3.4% | 2.2% | 4.3% |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.07 | 0.07 | 0.21 | 0.26 | 0.59 | — | — | — | — | — | — | — | — |
| Current Ratio | 4.24 | 4.24 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $40.3M | $40.3M | $38.1M | $33.4M | $3.3M | $528000.00 | $735000.00 | $-2.9M | $4.8M | $446000.00 | $6.3M | $1.8M | — |
| Returns | |||||||||||||
| ROE | 8.7% | 8.7% | 7.8% | 14.7% | -14.7% | -9.2% | -0.5% | 9.7% | 7.4% | 8.0% | 4.8% | -24.7% | -32.2% |
| Valuation | |||||||||||||
| P/E | 27.56 | 27.56 | 25.04 | 11.15 | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 12.59 | 12.59 | 11.55 | 11.61 | 175.71 | — | — | — | — | — | — | — | — |
| P/B | 2.55 | 2.55 | 1.95 | 1.64 | 2.11 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | 12.5% | 12.5% | 6.8% | 11.2% | — | 11.2% | -1.2% | 31.8% | 31.5% | 29.3% | 34.5% | 31.7% | — |
| EPS Growth | 17.1% | 17.1% | -43.1% | 238.2% | — | -1900.0% | -105.4% | 64.7% | 9.7% | 106.7% | 200.0% | -850.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
37.4%
EPS terminal req.
$2.13
Spread vs growth
-20.3%
5Y implied EPS CAGR
25.7%
EPS terminal req.
$2.57
Spread vs growth
-8.6%
10Y implied EPS CAGR
17.6%
EPS terminal req.
$4.15
Spread vs growth
-0.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+142.7%
Start / end P/E
14.1x → 29.2x
EPS bridge
0.70 → 0.82
Residual
+18.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.